Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression

References

• Adida C, Crotty PL, McGrath J, et al. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–9
   PubMed Web of Science ®Google Scholar
• Altieri DC, Marchisio PC. (1999). Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327–33
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP, Yu J, Simosa H, et al. (2002). Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8:987–94
   PubMed Web of Science ®Google Scholar
• Daniel JM, Dutzmann J, Bielenberg W, et al. (2012). Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 107:261
   Google Scholar
• Dawkins KD, Grube E, Guagliumi G, et al. (2005). Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112:3306–13
   PubMed Web of Science ®Google Scholar
• Dibra A, Kastrati A, Mehilli J, et al. (2005). Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353:663–70
   PubMed Web of Science ®Google Scholar
• Indolfi C, Cioppa A, Stabile E, et al. (2000). Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35:214–21
   PubMed Web of Science ®Google Scholar
• Kamihira S, Yamada Y. (2001). Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia. Leuk Lymphoma 41:169–76
   PubMed Web of Science ®Google Scholar
• Kastrati A, Dibra A, Eberle S, et al. (2005). Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 294:819–25
   PubMed Web of Science ®Google Scholar
• Katsaros KM, Wiesbauer F, Speidl WS, et al. (2011). High soluble Fas and soluble Fas ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost 105:883–91
   Google Scholar
• Komukai M, Wajima YS, Tashiro J, et al. (1999). Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Scand J Clin Lab Invest 59:159–66
   PubMed Web of Science ®Google Scholar
• Lansky AJ, Costa RA, Mooney M, et al. (2005). Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 45:1180–5
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY, et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–4
   PubMed Web of Science ®Google Scholar
• Luo Z, Garron T, Palasis M, et al. (2001). Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther 12:2191–202
   Google Scholar
• Makuuchi H, Furuse A, Endo M, et al. (2005). Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J 69:636–43
   PubMed Web of Science ®Google Scholar
• Matter CM, Chadjichristos CE, Meier P, et al. (2006). Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 113:1879–87
   PubMedGoogle Scholar
• Mehilli J, Kastrati A, Wessely R, et al. (2006). Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113:273–9
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, et al. (2002). A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–80
   PubMed Web of Science ®Google Scholar
• Preusch MR, Vanakaris A, Bea F, et al. (2010). Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur J Med Res 15:461–7
   Google Scholar
• Schafer K, Kaiser K, Konstantinides S. (2005). Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 93:145–52
   PubMed Web of Science ®Google Scholar
• Simosa HF, Wang G, Sui X, et al. (2005). Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. J Vasc Surg 41:682–90
   Google Scholar
• Takashima H, Nakajima T, Moriguchi M, et al. (2005). In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int 25:77–84
   Google Scholar
• Tokoro T, Wang J, Kitajima I. (2004). The novel HMG-CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO). Yakugaku Zasshi 124:121–6
   Google Scholar
• Wajima T, Makita S, Oshima K. (2003). Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Clin Exp Pharmacol Physiol 30:958–62
   PubMed Web of Science ®Google Scholar
• Wang GJ, Sui XX, Simosa HF, et al. (2005a). Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol 25:2081–7
   PubMed Web of Science ®Google Scholar
• Wang L, Chen J, Sun Y, et al. (2005b). Regulation of connexin expression after balloon injury: Possible mechanisms for antiproliferative effect of statins. Am J Hypertens 18:1146–53
   PubMed Web of Science ®Google Scholar
• Wang T, Dong C, Stevenson SC, et al. (2002). Overexpression of soluble Fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation 106:1536–42
   PubMed Web of Science ®Google Scholar
• Xia W, Bisi J, Strum J, et al. (2006). Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66:1640–7
   PubMed Web of Science ®Google Scholar
• Xu YG, Zhou SH, Li YG, et al. (2007). The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression. Cardiovasc Drugs Ther 21:145–53
   Google Scholar
• Yokoi H, Nobuyoshi M, Mitsudo K, et al. (2005). Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 69:875–83
   Google Scholar
• Yonesaka K, Tamura K, Kurata T, et al. (2006). Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 118:812–20
   PubMedGoogle Scholar